Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Patrício Manuel Vieira Araújo Soares Da Silva

    Autor

Participantes de fora da FMUP

  • Reichmann, H
  • Eggert, K
  • Oehlwein, C
  • Warnecke, T
  • Lees, AJ
  • Kemmer, M

Unidades de investigação

Abstract

Introduction: The OPTIPARK study confirmed the effectiveness and safety of opicapone as adjunct therapy to levodopa in patients with Parkinson's disease (PD) and motor fluctuations under real-world conditions. The aim of this sub-analysis was to evaluate opicapone in the German patient cohort of OPTIPARK in order to provide country-specific data. Methods: OPTIPARK was an open-label, single-arm study conducted in routine clinical practice across Germany and the UK. Patients with PD and motor fluctuations received once-daily opicapone 50 mg for 3 months in addition to levodopa. The primary endpoint was Clinicians' Global Impression of Change (CGI-C). Secondary assessments included Patients' Global Impressions of Change (PGI-C), Unified Parkinson's Disease Rating Scale (UPDRS) I-IV, Parkinson's Disease Questionnaire (PDQ-8), and Non-Motor Symptoms Scale (NMSS). This sub-analysis reports outcomes from the German patients only. Results: Overall, 363 (97.6%) of the 372 patients included in the German cohort received >= 1 dose of opicapone and 291 (80.2%) completed the study. Improvements on CGI-C and PGI-C were reported by 70.8% and 76.3% of patients, respectively. UPDRS scores improved for activities of daily living during OFF time by -3.3 +/- 4.5 points and motor scores during ON time by -5.3 +/- 7.9 points. PDQ-8 and NMSS scores also demonstrated improvements. Treatment emergent adverse events considered at least possibly related to opicapone occurred in 37.7% of patients, with most being of mild or moderate intensity. Conclusion: Opicapone added to levodopa in patients with PD and motor fluctuations was effective and generally well tolerated in routine clinical practice across Germany.

© 2022 The Author(s). Published by S. Karger AG, Basel.

Dados da publicação

ISSN/ISSNe:
1421-9913, 0014-3022

European Neurology  S. Karger AG

Tipo:
Article
Páginas:
389-397
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 2

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Levodopa; Motor fluctuations; Opicapone; Parkinson's disease; Real-world study

Financiamento

Proyectos asociados

Modelling Propofol pharmacokinetics and pharmacodynamics during an intravenous anaesthesia guided by the bispectral index (Bis)

Investigador Principal: Patrício Manuel Vieira Araújo Soares da Silva

Estudo Clínico Académico . 2021

Inervação simpática e mecanismos adrenérgicos locais na regulação funcional da córnea

Investigador Principal: Patrício Manuel Vieira Araújo Soares da Silva

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação